Nightingale’s biomarker analysis platform has helped researchers from diverse fields to identify new associations, predict diseases or enhance gene discoveries. Explore what Nightingale's analysis can do for you in your field of research.
Nightingale’s blood panel has been used by numerous CVD researchers globally. By providing comprehensive coverage of detailed lipid measures and metabolites, our platform is a powerful tool for studies focusing on disease prediction and risk model development, disease etiology, drug development, translation, and combining genomics data with metabolic data. For example, studies have characterized biomarker differences for common types of CVD and clarified the molecular effects of known and novel lipid-lowering drugs.
Our biomarkers include an advanced lipid panel with 14 lipoprotein subclasses, fatty acids, inflammation marker–GlycA along with other key CVD biomarkers, clinically validated biomarkers for fast translation (like omega-3, ApoA1, and ApoB) and numerous emerging markers such as ketones and amino acids.
Tikkanen et al, medRxiv 2020
Balling et al, J Am Coll Cardiol 2020
Wang et al, European Heart Journal 2021
Nightingale’s blood and urine biomarker panels are versatile tools for diabetes research. Our blood panel has been used in numerous publications on type 1 and type 2 diabetes, as well as their complications and underlying risk factors. These studies include the early metabolic dysregulation associated with adiposity, insulin resistance, and the spectrum of hyperglycemia. Other studies have focused on predicting type 2 diabetes risk among various ethnic groups and molecular characterization of genes for predisposition to diabetes.
Both the blood and urine panels include amino acids and glycolysis-related metabolites for easy comparison of the function on both sides of the kidney. In addition, our blood panel also provides inflammation marker GlycA, an advanced lipid panel with 14 lipoprotein subclasses, and clinically validated biomarkers for fast translation. The urine panel has been used to identify novel biomarkers for the progression of diabetic kidney disease.
Bragg et al, medRxiv 2021
Hoong Seah et al, medRxiv 2021
Mutter et al, Diabetologia 2021
Nightingale's technology is ideal for genomics research since it has excellent scalability and comprehensive coverage of metabolic pathways. The technology provides established biomarkers for cardiovascular diseases, diabetes, and other chronic diseases. Additionally, we deliver results for emerging biomarkers that enable new discoveries in fields like neurological diseases and gut research.
Our technology has a wide variety of possible applications in genomics research, including genome-wide association studies (GWAS) at biobank scale and complementing sequencing data with Nightingale's metabolomics biomarkers to facilitate genetic discoveries. The technology is also suitable for assessing the causality of biomarkers in disease development and can contribute to improving clinical success rates in drug development.
Vojinovic et al. Neurology. 2020 Dec 2;96(8):e1110–23
Locke et al. Nature 2019; Jul 31
Ference et al. N Engl J Med 2019;380:1033-1042
Nightingale’s metabolomics data has been used in several studies to identify the connection between metabolic health and ageing. For instance, our blood panel has been used to identify the impact of lifestyle choices on metabolic health and age in older populations. The platform is also suitable for studies focusing on distinct research areas such as menopause and dementia.
Our blood panel includes amino acids and a comprehensive lipid profile providing insights on the changing metabolism and its effect on aging. Our CSF panel consists of several small molecular weight metabolites that overlap with our blood panel, enabling easy comparison between the two circulating systems.
Van de Rest et al. Aging 2016;8(1):111-24
Wang et al. BMC Medicine 2018;16:17
Nightingale’s blood panel includes many biomarkers that relate to the body’s overall immune system. These include both established markers of chronic inflammation, such as GlycA, and novel metabolic biomarkers that strongly reflect the susceptibility to infectious diseases including severe COVID-19. The biomarkers capture ageing processes and overall frailty, but the changes in the biomarkers are already visible in population studies of generally healthy people. Even stronger results are observed in patients with prevalent disease – for example, the same biomarkers can strongly stratify COVID-19 severity in hospital settings.
Ritchie et al. Cell Systems 2015:1(4);293-301
Deelen et al., NAT COMMUN 2019;10:3346
Locke et al. Nature 2019; Jul 31
Nightingale’s platform is an excellent tool to research the relationship between mother and child, and particularly to study metabolite transport between the two systems. Analysing blood, cord blood and urine enables studying the effects of the offspring’s short- and long-term metabolism and how that correlates with lifelong health. In addition, it enables studying pregnancy-related complications like pre-eclampsia and gestational diabetes.
All this is made possible by our extensive panels which contain several metabolites that support meaningful examination of pregnancy complications such as lipids, amino acids, glycolysis related metabolites and lipoprotein particles.
Taylor et al. Metabolites 2019;9(9):190
White et al. Diabetologia 2017;60(10):1903-12
Wang et al. BMC Medicine 2018;16:17
Nightingale’s metabolic profiling is an excellent tool for various types of studies such as post-prandial studies and interventions searching for links between dietary intake and health outcomes. This insight of metabolite-level changes enhance understanding why certain foods or nutrients associate with diseases in epidemiological studies.
Nightingale’s blood panel covers a vast range of metabolites, such as the detailed lipid subclasses, amino acids, fatty acids, and inflammatory markers that respond to changes in dietary intake. Our novel urine platform includes several metabolites that may prove useful as biomarkers of food and nutrient intake such as proline betaine (fruit and vegetables), TMAO (meat), and sucrose (sugar).
Lehtovirta et al. The Journal of Pediatrics 2018;195:190-198.e3
Michielsen et al. Mol Nutr Food Res. 2019;63(9):e1801095
Beynon et al. 2018;144:1918–1928
Nightingale’s metabolic profiling provides a broad overview of the host’s systemic metabolism. This enables exploring new connections between gut microbes, nutrition and different areas of health, and can help to understand the function of gut microbial species. Our platform has been used in published research on gut microbial associations in metabolic syndrome, CVD and pregnancy as well for studying disease progression for inflammatory bowel disease.
In addition, to covering the major biological pathways, our blood and urine analysis also includes biomarkers that are of special interest to gut research; acetate and inflammation biomarker from blood like GlycA, as well as TMAO, dimethylamine and lactate from urine.
ORG ET AL. GENOME BIOLOGY 2017;18:70
Dierckx et al. JCC 2019;13(3):389–394
Röytiö et al. British Journal of Nutrition 2017;118(5):343-352